[Skip to the reading](#reading)

Online peptide providers

A reading guide to online care

Medicine names

# A medicine name changes the conversation.

Write down the medicine’s whole name. Ask: “Is this a shot, a tablet or something else?” A broad phrase such as peptide treatment leaves too much open.

## Keep the words apart

**Active ingredient**

Active ingredient names the substance doing the medicine’s work.

**Compounding**

Compounding makes a patient’s medicine by preparing or altering it in a pharmacy or a doctor’s practice.

**Product approval**

Before approval, FDA (Food and Drug Administration) reviews the evidence for that exact medicine. It must work and be safe enough for the health problem named in the approval, as of 26 September 2026.

For example, FDA-approved products as of 26 September 2026 include tirzepatide (Mounjaro, Zepbound), alongside semaglutide (Ozempic, Wegovy).

## A compounded product has a different status

A compounded medicine has no FDA approval as of 26 September 2026. FDA does not check its safety, how well it is made or whether it works before it goes on sale.

If an approved medicine does not meet a patient’s needs, there may be a reason to consider compounding, as of 26 September 2026.

Ask: “Why would the approved, ready-made medicine not meet my need? What would the pharmacy change for me? Which rule allows that change?”

For pharmacies making medicines for named patients, price alone cannot justify routinely copying a medicine already sold ready-made. The person writing the prescription must judge that a change makes a significant difference to that patient. This rule was checked on 26 September 2026.

## Look for “research use only” on a label

Some sellers labelled products “research use only” while marketing them for people to use. Another label said “not for human consumption”. That means people are not meant to use it. In warning letters reviewed on 26 September 2026, FDA said those labels did not change that the products were being sold as unapproved drugs.

These letters give FDA’s accusations against particular sellers. They contain no court ruling.

Bring the question back to your care: “Which exact medicine are you offering me?” A page about research chemicals does not answer who will check your health or follow up.

[Find out who would fill the order](/pharmacy-map/)

## Where these notes come from

- [FDA on why compounding is different](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers)

- [FDA notes on online weight-drug offers](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss)

- [FDA on the meaning of approval](https://www.fda.gov/consumers/consumer-updates/it-really-fda-approved)

Next in the map [The pharmacy check →](/pharmacy-map/)

This care guide sorts questions into a reading map; it offers neither clinic appointments nor medicines.

The reading map

- [The opening page](/)

- [The care map](/map/)

- [Screen or room](/forks-in-the-road/)

- [The person treating you](/licence-map/)

- [Visit notes](/visit-map/)

- [Tests and labs](/testing-route/)

- [Medicine names](/medicine-map/)

- [The pharmacy check](/pharmacy-map/)

- [Costs and cover](/cost-map/)

- [Follow-up](/follow-up-map/)

- [Reasons to pause](/red-flag-route/)